Turnstone Biologics
TSBX
TSBX was delisted on the 8th of August, 2025.
35 hedge funds and large institutions have $48M invested in Turnstone Biologics in 2023 Q3 according to their latest regulatory filings, with 35 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
53.43% more ownership
Funds ownership: 0% → 53.43% (+53%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$27.6M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$25.2M |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$13.6M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$7.43M |
| 5 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$6.31M |
Top Sellers
TSBX Hedge Fund Activity: Q3 2023 in Review
35 of the 6,311 institutional investors tracked by Wall St. Rank reported a position in Turnstone Biologics (TSBX) for Q3 2023, worth a combined $48M.
Buyers outnumbered sellers: 35 funds opened new TSBX positions and 0 closed out — a net gain of 35 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $27.6M.
- 35 institutional investors held Turnstone Biologics (TSBX) as of Q3 2023, up from 0 in Q2 2023.
- Funds reported $48M of Turnstone Biologics stock for Q3 2023.
- 35 funds opened new Turnstone Biologics positions in Q3 2023 and 0 closed out, a net change of +35 holders.
- The largest Turnstone Biologics buyer in Q3 2023 was OrbiMed, an estimated $27.6M added.
Based on aggregated 13F filings for Q3 2023.